Catalina Capital Group LLC Grows Holdings in Amgen Inc. (NASDAQ:AMGN)

Catalina Capital Group LLC lifted its position in shares of Amgen Inc. (NASDAQ:AMGN) by 10.1% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 2,330 shares of the medical research company’s stock after buying an additional 213 shares during the quarter. Catalina Capital Group LLC’s holdings in Amgen were worth $751,000 at the end of the most recent quarter.

Other institutional investors have also modified their holdings of the company. Hershey Financial Advisers LLC purchased a new position in shares of Amgen during the 2nd quarter worth $30,000. nVerses Capital LLC purchased a new position in shares of Amgen during the 2nd quarter worth about $31,000. Bbjs Financial Advisors LLC acquired a new stake in shares of Amgen in the second quarter worth approximately $33,000. Matrix Trust Co purchased a new stake in Amgen in the third quarter valued at approximately $36,000. Finally, FSA Wealth Management LLC increased its position in Amgen by 182.0% during the first quarter. FSA Wealth Management LLC now owns 141 shares of the medical research company’s stock worth $40,000 after purchasing an additional 91 shares during the last quarter. Institutional investors and hedge funds own 76.50% of the company’s stock.

Wall Street Analyst Weigh In

AMGN has been the subject of a number of research reports. Barclays boosted their price target on Amgen from $300.00 to $315.00 and gave the company an “equal weight” rating in a research report on Monday, October 7th. Bank of America boosted their target price on Amgen from $325.00 to $330.00 and gave the stock a “neutral” rating in a report on Wednesday, August 7th. Robert W. Baird restated an “underperform” rating and issued a $215.00 price target on shares of Amgen in a report on Wednesday, September 25th. Sanford C. Bernstein assumed coverage on shares of Amgen in a research report on Thursday, October 17th. They issued an “outperform” rating and a $380.00 price objective for the company. Finally, Wells Fargo & Company lowered shares of Amgen from an “overweight” rating to an “equal weight” rating and lifted their target price for the company from $320.00 to $335.00 in a report on Wednesday, August 7th. One equities research analyst has rated the stock with a sell rating, eleven have given a hold rating, eleven have given a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat.com, Amgen presently has an average rating of “Moderate Buy” and an average target price of $333.50.

Amgen Trading Up 0.8 %

Shares of NASDAQ:AMGN opened at $319.29 on Wednesday. Amgen Inc. has a fifty-two week low of $260.52 and a fifty-two week high of $346.85. The company has a quick ratio of 0.96, a current ratio of 1.32 and a debt-to-equity ratio of 7.55. The company has a market cap of $171.56 billion, a PE ratio of 40.88, a P/E/G ratio of 2.81 and a beta of 0.60. The company’s 50-day moving average price is $324.12 and its 200 day moving average price is $316.64.

Amgen (NASDAQ:AMGN) last posted its earnings results on Wednesday, October 30th. The medical research company reported $5.58 EPS for the quarter, beating the consensus estimate of $5.11 by $0.47. Amgen had a return on equity of 168.35% and a net margin of 13.00%. The firm had revenue of $8.50 billion for the quarter, compared to analysts’ expectations of $8.50 billion. During the same period last year, the firm earned $4.96 EPS. The firm’s revenue was up 23.2% compared to the same quarter last year. Sell-side analysts anticipate that Amgen Inc. will post 19.49 earnings per share for the current year.

Amgen Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, December 9th. Stockholders of record on Monday, November 18th will be paid a $2.25 dividend. This represents a $9.00 dividend on an annualized basis and a dividend yield of 2.82%. The ex-dividend date is Monday, November 18th. Amgen’s dividend payout ratio is currently 115.24%.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.